Halozyme Therapeutics Inc (NASDAQ:HALO) shares, rose in value on Friday, January 24, with the stock price up by 0.25% to the previous day’s close as strong demand from buyers drove the stock to $55.77.
Actively observing the price movement in the last trading, the stock closed the session at $55.63, falling within a range of $54.975 and $56.0799. The value of beta (5-year monthly) was 1.29 whereas the PE ratio was 18.45 over 12-month period. Referring to stock’s 52-week performance, its high was $65.53, and the low was $33.15. On the whole, HALO has fluctuated by 18.76% over the past month.
With the market capitalization of Halozyme Therapeutics Inc currently standing at about $7.10 billion, investors are eagerly awaiting this quarter’s results, scheduled for in February.
Projections by analysts suggest varying estimates for the company’s quarterly revenue. Analysts have estimated the company’s revenue for the quarter at 1B, with a low estimate of 270M and a high estimate of 306.27M. Wall Street analysts also predicted that the company’s y-o-y revenues would reach 285.74M.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that HALO’s technical picture suggests that short-term indicators denote the stock is a 50% Buy on average. However, medium-term indicators have put the stock in the category of 50% Sell while long-term indicators on average have been pointing out that it is a 100% Buy.
The stock’s technical analysis shows that the price of HALO currently trading nearly 7.38% and 11.26% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 68.00, while the 7-day volatility ratio is showing 2.00% which for the 30-day chart, stands at 2.73%. Furthermore, Halozyme Therapeutics Inc (HALO)’s beta value is 1.26, and its average true range (ATR) is 1.51.
A comparison of Halozyme Therapeutics Inc (HALO) with its peers suggests the former has fared considerably weaker in the market. HALO showed an intraday change of 0.25% in last session, and over the past year, it grew by 60.49%%.
Data on historical trading for Halozyme Therapeutics Inc (NASDAQ:HALO) indicates that the trading volumes over the past 10 days have averaged 1.4 and over the past 3 months, they’ve averaged 1.69 million. According to company’s latest data on outstanding shares, there are 127.18 million shares outstanding.
Nearly 1.05% of Halozyme Therapeutics Inc’s shares belong to company insiders and institutional investors own 99.69% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 9.5 million shares as on 2024-12-31, resulting in a short ratio of 7.28. According to the data, the short interest in Halozyme Therapeutics Inc (HALO) stood at 1011.00 of shares outstanding as of 2024-12-31; the number of short shares registered in 2024-11-29 reached 8.57 million. The stock has risen by 16.65% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the HALO stock heading into the next quarter.
